Skip to main content

Table 5 Cytotoxicity of compounds 9, 10, 11a, 11b, 12, 13, 14 and 15 against breast carcinoma cell line MCF-7

From: Design, synthesis and evaluation of anticancer activity of novel 2-thioxoimidazolidin-4-one derivatives bearing pyrazole, triazole and benzoxazole moieties

Concentration µg/mL

Viability (%)/compound

9

10

11a

11b

12

13

14

500

8.09

6.48

31.79

8.51

6.37

5.96

5.08

250

17.24

15.72

49.81

20.38

14.75

11.74

10.24

125

26.85

24.16

78.26

32.75

23.81

20.82

18.76

62.5

37.51

35.29

89.47

45.06

34.93

27.41

24.95

31.25

45.97

42.81

95.24

61.78

40.84

34.92

30.88

15.6

57.20

51.56

99.71

79.39

49.60

44.73

36.78

7.8

74.19

69.37

100

92.64

70.38

65.46

42.97

3.9

88.43

86.02

100

98.25

81.49

79.25

51.36

2

95.72

93.88

100

100

92.63

90.48

59.28

1

99.34

97.40

100

100

96.75

96.23

72.83

0

100

100

100

100

100

100

100

Back to article page

BMC Chemistry

ISSN: 2661-801X

Contact us